{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:19:58Z","timestamp":1792153198940,"version":"4.4.0"},"reference-count":232,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109129","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:59:48Z","timestamp":1761353988000},"page":"109129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapeutic innovation through drug repurposing: A multidimensional approach toward treating Parkinson's disease"],"prefix":"10.1016","volume":"166","author":[{"given":"Saswati Swagatika","family":"Sahoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir Kumar","family":"Paidesetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratap Kumar","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swagata","family":"Pattanaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rambabu","family":"Dandela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109129_bb0005","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1016\/S2666-7568(24)00094-1","article-title":"Temporal trends in the prevalence of Parkinson\u2019s disease from 1980 to 2023: a systematic review and meta-analysis","volume":"5","author":"Zhu","year":"2024","journal-title":"Lancet Healthy Longevity"},{"key":"10.1016\/j.bioorg.2025.109129_bb0010","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00500-025-10463-9","article-title":"Comprehensive multimodal approach for Parkinson\u2019s disease classification using artificial intelligence: insights and model explainability","volume":"29","author":"Balaha","year":"2025","journal-title":"Soft. Comput."},{"key":"10.1016\/j.bioorg.2025.109129_bb0015","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s10072-023-07205-w","article-title":"Imbalance and gait impairment in Parkinson\u2019s disease: discussing postural instability and ataxia","volume":"45","author":"Camargo","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0020","series-title":"Essential Guide to Neurodegenerative Disorders","first-page":"269","article-title":"Non-motor symptoms of Parkinson\u2019s disease","author":"El-Mansoury","year":"2025"},{"key":"10.1016\/j.bioorg.2025.109129_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101834","article-title":"Dos Santos, premotor, nonmotor and motor symptoms of Parkinson\u2019s disease: A new clinical state of the art","volume":"84","author":"Leite Silva","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bioorg.2025.109129_bb0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41582-024-01043-w","article-title":"\u03b1-Synuclein pathology as a target in neurodegenerative diseases","volume":"21","author":"Park","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.prmcm.2024.100499","article-title":"A comprehensive review and recent advancement in the application of tannins for treating Parkinson disease","volume":"12","author":"Satapathy","year":"2024","journal-title":"Pharmacological Research - Modern Chinese Medicine"},{"key":"10.1016\/j.bioorg.2025.109129_bb0040","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1007\/s00415-022-10963-w","article-title":"Levodopa-induced dyskinesia: a historical review of Parkinson\u2019s disease, dopamine, and modern advancements in research and treatment","volume":"269","author":"Hansen","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0045","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.3390\/cells11233736","article-title":"Levodopa-induced dyskinesia in Parkinson\u2019s disease: pathogenesis and emerging treatment strategies","volume":"11","author":"Kwon","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109129_bb0050","doi-asserted-by":"crossref","first-page":"7183","DOI":"10.3390\/ijms25137183","article-title":"A comprehensive approach to Parkinson\u2019s disease: addressing its molecular, clinical, and therapeutic aspects","volume":"25","author":"Muleiro Alvarez","year":"2024","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2025.109129_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102698","article-title":"Repurposing drugs: promising therapeutic approach against Alzheimer\u2019s disease","volume":"106","author":"Pattanaik","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bioorg.2025.109129_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117862","article-title":"An update on drug repurposing in Parkinson\u2019s disease: preclinical and clinical considerations","volume":"183","author":"Salvad\u00e8","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109129_bb0065","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/acsptsci.3c00361","article-title":"Drug repurposing: A leading strategy for new threats and targets","volume":"7","author":"Mishra","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109129_bb0075","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","article-title":"Emerging therapies in Parkinson disease \u2014 repurposed drugs and new approaches","volume":"15","author":"Elkouzi","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0080","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0085","doi-asserted-by":"crossref","DOI":"10.4103\/NRR.NRR-D-24-00941","article-title":"Neuroprotective effects of lixisenatide against propagation of \u03b1-synuclein pathology in Parkinson\u2019s disease","author":"Sun","year":"2025","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.bioorg.2025.109129_bb0090","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10787-023-01400-z","article-title":"The effects of cholesterol and statins on Parkinson\u2019s neuropathology: a narrative review","volume":"32","author":"Al-kuraishy","year":"2024","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.bioorg.2025.109129_bb0095","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10534-025-00693-7","article-title":"Ferrous sulfate and lipopolysaccharide co-exposure induce neuroinflammation, neurobehavioral motor deficits, neurodegenerative and histopathological biomarkers relevant to Parkinson\u2019s disease-like symptoms in Wistar rats","volume":"38","author":"Pandey","year":"2025","journal-title":"Biometals"},{"key":"10.1016\/j.bioorg.2025.109129_bb0100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-025-03462-y","article-title":"Microglial dynamics and neuroinflammation in prodromal and early Parkinson\u2019s disease","volume":"22","author":"Lind-Holm Mogensen","year":"2025","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bioorg.2025.109129_bb0105","doi-asserted-by":"crossref","first-page":"053","DOI":"10.69613\/t3q3nv23","article-title":"Malgunde Swati Pandurang, tamboli najiya jakir, current perspectives on pathogenesis, clinical manifestations, and treatment of parkinson\u2019s disease: review article","volume":"3","author":"Chaudhari Sakshi Dattatraya","year":"2025","journal-title":"JOPIR"},{"key":"10.1016\/j.bioorg.2025.109129_bb0110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41582-025-01090-x","article-title":"Dementia with Lewy bodies and Parkinson disease dementia \u2014 the same or different and is it important?","volume":"21","author":"Fu","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0115","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s11033-024-09520-7","article-title":"Interplay between \u03b1-synuclein and parkin genes: insights of Parkinson\u2019s disease","volume":"51","author":"Sharma","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bioorg.2025.109129_bb0120","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Mahul-Mellier","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2025.109129_bb0125","article-title":"Prions and neurodegenerative diseases: mechanisms of protein Misfolding and spread","volume":"1","author":"Mi","year":"2025","journal-title":"MS"},{"key":"10.1016\/j.bioorg.2025.109129_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13024-025-00868-3","article-title":"Alpha-synuclein seeding amplification assays in Lewy body dementia: a brief review","volume":"20","author":"Bregendahl","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bioorg.2025.109129_bb0135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s42269-023-01047-4","article-title":"A detailed review of pathophysiology, epidemiology, cellular and molecular pathways involved in the development and prognosis of Parkinson\u2019s disease with insights into screening models","volume":"47","author":"Sayyaed","year":"2023","journal-title":"Bull. Natl. Res. Cent."},{"key":"10.1016\/j.bioorg.2025.109129_bb0140","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.5c00356","article-title":"The aggregation continuum of \u03b1-Synuclein and its relevance to brain aging","author":"Rana","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0145","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251339895","article-title":"Decoding crosstalk between neurotransmitters and \u03b1-synuclein in Parkinson\u2019s disease: pathogenesis and therapeutic implications","volume":"18","author":"Guan","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bioorg.2025.109129_bb0150","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-025-08421-2","article-title":"Converging pathologies in neurodegeneration: the mechanistic interplay between \u03b1-Synuclein and Tau in Alzheimer\u2019s and Parkinson\u2019s","author":"Jeyabalan","year":"2025","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0155","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1186\/s12967-025-06354-0","article-title":"Recent advances in targeting LRRK2 for Parkinson\u2019s disease treatment","volume":"23","author":"Karami","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.109129_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105837","article-title":"The multifaceted role of LRRK2 in Parkinson\u2019s disease: from human iPSC to organoids","volume":"173","author":"Oun","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioorg.2025.109129_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.70074","article-title":"The Parkinson disease-associated mutant DNAJC13(N855S) leads to its accelerated degradation and negatively affects macroautophagy and Retromer complex-mediated dynamics","volume":"240","author":"Stein","year":"2025","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11064-025-04490-z","article-title":"Mitochondrial damage and autophagy dysregulation in Alzheimer\u2019s disease: mechanisms and therapeutic opportunities","volume":"50","author":"Yu","year":"2025","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bioorg.2025.109129_bb0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s13258-024-01506-w","article-title":"DJ-1 protects cell death from a mitochondrial oxidative stress due to GBA1 deficiency","volume":"46","author":"Nam","year":"2024","journal-title":"Genes Genom."},{"key":"10.1016\/j.bioorg.2025.109129_bb0180","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2174\/1389203717666160311122152","article-title":"Other proteins involved in Parkinson\u2019s disease and related disorders","volume":"18","author":"Cardona","year":"2017","journal-title":"CPPS"},{"key":"10.1016\/j.bioorg.2025.109129_bb0185","article-title":"Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants, brain","volume":"6","author":"Houldsworth","year":"2023","journal-title":"Communications"},{"key":"10.1016\/j.bioorg.2025.109129_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1158198","article-title":"Oxidative stress, free radicals and antioxidants: potential crosstalk in the pathophysiology of human diseases","volume":"11","author":"Chaudhary","year":"2023","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2025.109129_bb0195","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2174\/1381612827666210119103545","article-title":"Protective effects of hydrogen against irradiation","volume":"27","author":"Terasaki","year":"2021","journal-title":"CPD"},{"key":"10.1016\/j.bioorg.2025.109129_bb0200","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajme.2017.09.001","article-title":"First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): their fundamental role in the entire antioxidant defence grid","volume":"54","author":"Ighodaro","year":"2018","journal-title":"Alexandria J. Med."},{"key":"10.1016\/j.bioorg.2025.109129_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9163040","article-title":"The sources of reactive oxygen species and its possible role in the pathogenesis of Parkinson\u2019s disease","volume":"2018","author":"Weng","year":"2018","journal-title":"Parkinson\u2019s Dis."},{"key":"10.1016\/j.bioorg.2025.109129_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102660","article-title":"The emerging role of oxygen redox in pathological progression of disorders","volume":"104","author":"Li","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bioorg.2025.109129_bb0215","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41573-024-01105-0","article-title":"Targeting mitophagy in neurodegenerative diseases","volume":"24","author":"Antico","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109129_bb0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12993-025-00279-w","article-title":"Neurodegeneration models in Parkinson\u2019s disease: cellular and molecular paths to neuron death","volume":"21","author":"\u00c1lvarez-Luqu\u00edn","year":"2025","journal-title":"Behav. Brain Funct."},{"key":"10.1016\/j.bioorg.2025.109129_bb0225","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12967-025-06605-0","article-title":"Targeting mitochondria with natural polyphenols for treating neurodegenerative diseases: a comprehensive scoping review from oxidative stress perspective","volume":"23","author":"Guan","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.109129_bb0230","first-page":"1","article-title":"Oxidative stress and Neuroinflammation potentiate each other to promote progression of dopamine neurodegeneration","volume":"2020","author":"He","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2025.109129_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.104982","article-title":"The effect of aged microglia on synaptic impairment and its relevance in neurodegenerative diseases","volume":"144","author":"Trivi\u00f1o","year":"2021","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bioorg.2025.109129_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102134","article-title":"The Nrf2-NLRP3-caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson\u2019s disease","volume":"47","author":"Zhang","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0245","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-020-15119-w","article-title":"Microglia clear neuron-released \u03b1-synuclein via selective autophagy and prevent neurodegeneration","volume":"11","author":"Choi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109129_bb0250","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/ijms22031062","article-title":"Pathomechanism characterization and potential therapeutics identification for Parkinson\u2019s disease targeting Neuroinflammation","volume":"22","author":"Chen","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2025.109129_bb0255","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10522-025-10199-x","article-title":"Neuroinflammaging and the immune landscape: the role of autophagy and senescence in aging brain","volume":"26","author":"Tamatta","year":"2025","journal-title":"Biogerontology"},{"key":"10.1016\/j.bioorg.2025.109129_bb0260","series-title":"NeuroPsychopharmacotherapy","first-page":"2823","article-title":"Definition and classification of parkinsonian drugs","author":"Mizuno","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109129_bb0265","first-page":"847","article-title":"Treatment of Parkinson\u2019s disease by MAO-B inhibitors","volume":"23","author":"Parambi","year":"2020","journal-title":"New Therapies Future Challenges - A Mini-Review, CCHTS"},{"key":"10.1016\/j.bioorg.2025.109129_bb0270","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11033-025-10349-x","article-title":"Molecular pathways: the quest for effective MAO-B inhibitors in neurodegenerative therapy","volume":"52","author":"Oyovwi","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bioorg.2025.109129_bb0275","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/1062936X.2025.2537248","article-title":"Targeting MAO-B selectivity: computational screening, docking, and molecular dynamics insights","volume":"36","author":"Thai","year":"2025","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.bioorg.2025.109129_bb0280","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/1060028020974560","article-title":"Opicapone (Ongentys): A new COMT inhibitor for the treatment of Parkinson\u2019s disease","volume":"55","author":"St","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109129_bb0285","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/14656566.2022.2060738","article-title":"What is the impact of catechol-O-methyltransferase (COMT) on Parkinson\u2019s disease treatment?","volume":"23","author":"Salamon","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109129_bb0290","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41551-022-00987-y","article-title":"Challenges in the clinical advancement of cell therapies for Parkinson\u2019s disease","volume":"7","author":"Skidmore","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioorg.2025.109129_bb0295","article-title":"Parkinson\u2019s disease: from bench to bedside-advancements in diagnosis and therapeutics using Pharmacogenomic approach","volume":"25","author":"Kadiri","year":"2025","journal-title":"CGT"},{"key":"10.1016\/j.bioorg.2025.109129_bb0300","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0000000000000628","article-title":"Amantadine reduces adverse cardiovascular outcomes in patients with parkinsonism or Parkinson disease: A global propensity score matched analysis","volume":"48","author":"Draytsel","year":"2025","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0305","series-title":"NeuroPsychopharmacotherapy","first-page":"3333","article-title":"Trihexyphenidyl, Biperiden, and other anticholinergics in the treatment of Parkinson\u2019s disease","author":"Kawabata","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109129_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102693","article-title":"Does drug repurposing bridge the gaps in management of Parkinson\u2019s disease? Unravelling the facts and fallacies","volume":"105","author":"Bashir","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bioorg.2025.109129_bb0315","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.parkreldis.2020.10.023","article-title":"Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems","volume":"80","author":"Pinna","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bioorg.2025.109129_bb0320","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.parkreldis.2020.10.027","article-title":"The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant","volume":"80","author":"LeWitt","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bioorg.2025.109129_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.602697","article-title":"Caffeine and Parkinson\u2019s disease: multiple benefits and emerging mechanisms","volume":"14","author":"Ren","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0330","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/09727531221136349","article-title":"Future of monoclonal antibody therapy in Parkinson\u2019s disease","volume":"30","author":"Kharel","year":"2023","journal-title":"Ann. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.705407","article-title":"PASADENA investigators, Prasinezumab study group, A phase II study to evaluate the safety and efficacy of Prasinezumab in early Parkinson\u2019s disease (PASADENA): rationale, design, and baseline data","volume":"12","author":"Pagano","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0340","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209137","article-title":"Cinpanemab in early Parkinson disease: evaluation of biomarker results from the phase 2 SPARK clinical trial","volume":"102","author":"Hutchison","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.bioorg.2025.109129_bb0345","doi-asserted-by":"crossref","first-page":"113","DOI":"10.14802\/jmd.25008","article-title":"Drug repositioning and repurposing for disease-modifying effects in Parkinson\u2019s disease","volume":"18","author":"Jeong","year":"2025","journal-title":"JMD"},{"key":"10.1016\/j.bioorg.2025.109129_bb0350","first-page":"15","article-title":"Computational approaches to drug repurposing: methods, challenges, and opportunities, annual review of biomedical data","volume":"7","author":"Cousins","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.109129_bb0355","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1007\/s12035-023-03359-y","article-title":"Type 2 diabetes (T2DM) and Parkinson\u2019s disease (PD): a mechanistic approach","volume":"60","author":"Sabari","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0360","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.parkreldis.2020.08.018","article-title":"Peripheral insulin and amylin levels in Parkinson\u2019s disease","volume":"79","author":"S\u00e1nchez-G\u00f3mez","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bioorg.2025.109129_bb0365","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/ph18040486","article-title":"Overview of metformin and neurodegeneration: A comprehensive review","volume":"18","author":"Kruczkowska","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2025.109129_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.838173","article-title":"Exploring the pharmacological potential of metformin for neurodegenerative diseases","volume":"14","author":"Du","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108415","article-title":"Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinso\u0144s disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity","volume":"102","author":"Mendon\u00e7a","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0380","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neures.2019.12.017","article-title":"Neuroprotective effect of metformin on dopaminergic neurodegeneration and \u03b1-synuclein aggregation in C. elegans model of Parkinson\u2019s disease","volume":"162","author":"Saewanee","year":"2021","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.bioorg.2025.109129_bb0385","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13340-021-00519-0","article-title":"The forgotten type 2 diabetes mellitus medicine: rosiglitazone","volume":"13","author":"Xu","year":"2022","journal-title":"Diabetol. Int."},{"key":"10.1016\/j.bioorg.2025.109129_bb0390","series-title":"Repurposing Anti-Diabetic Drugs for the Treatment of Parkinson\u2019s Disease: Rationale and Clinical Experience","first-page":"493","year":"2020"},{"key":"10.1016\/j.bioorg.2025.109129_bb0395","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s13346-024-01558-1","article-title":"Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer\u2019s disease therapy","volume":"14","author":"Wong","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.bioorg.2025.109129_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134567","article-title":"Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson\u2019s disease","volume":"714","author":"Fine","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bioorg.2025.109129_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118159","article-title":"Intranasal insulin ameliorates cognitive impairment in a rat model of Parkinson\u2019s disease through Akt\/GSK3\u03b2 signaling pathway","volume":"259","author":"Yang","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0410","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: A new treatment in Parkinson\u2019s disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2025.109129_bb0415","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11011-021-00879-1","article-title":"Neuroprotective effects of liraglutide against inflammation through the AMPK\/NF-\u03baB pathway in a mouse model of Parkinson\u2019s disease","volume":"37","author":"Cao","year":"2022","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.bioorg.2025.109129_bb0420","doi-asserted-by":"crossref","first-page":"104","DOI":"10.21608\/ijabmb.2025.389792.1015","article-title":"Pharmacological insights into dipeptidyl Peptidase-4 inhibitors: therapeutic applications and future perspectives","volume":"2","author":"Fahmy","year":"2025","journal-title":"Int. J. Appl. Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0425","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1007\/s11357-024-01116-0","article-title":"DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson\u2019s disease","volume":"46","author":"Yu","year":"2024","journal-title":"GeroScience"},{"key":"10.1016\/j.bioorg.2025.109129_bb0430","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00702-025-02907-1","article-title":"Sitagliptin attenuates L-dopa-induced dyskinesia by regulating mitochondrial proteins and neuronal activity in a 6-OHDA-induced mouse model of Parkinson\u2019s disease","volume":"132","author":"Park","year":"2025","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bioorg.2025.109129_bb0435","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1021\/acschemneuro.5c00112","article-title":"Upregulation of the PI3K\/AKT and Nrf2 pathways by the DPP-4 inhibitor Sitagliptin renders neuroprotection in chemically induced Parkinson\u2019s disease mouse models","volume":"16","author":"Soni","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2022.113015","article-title":"Omarigliptin attenuates rotenone-induced Parkinson\u2019s disease in rats: possible role of oxidative stress, endoplasmic reticulum stress and immune modulation","volume":"164","author":"Michel","year":"2022","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0445","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109129_bb0450","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","article-title":"Targeting ROS-dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 pathways by Dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson\u2019s disease rat model","volume":"12","author":"Arab","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110002","article-title":"Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson\u2019s disease in rats: targeting the GRP78\/PERK\/eIF2\u03b1\/CHOP pathway and miR-211-5p","volume":"362","author":"Motawi","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2025.109129_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121258","article-title":"Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: role of BDNF, CREB and Npas4","volume":"312","author":"Mousa","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0465","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/ijms23010398","article-title":"Metformin repurposing for Parkinson disease therapy: opportunities and challenges","volume":"23","author":"Agostini","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2025.109129_bb0470","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1734-1140(10)70357-1","article-title":"Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide","volume":"62","author":"\u0141abuzek","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bioorg.2025.109129_bb0475","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00280-013-2084-2","article-title":"The PPAR\u03b3 agonist pioglitazone crosses the blood\u2013brain barrier and reduces tumor growth in a human xenograft model","volume":"71","author":"Grommes","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0480","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1038\/srep09000","article-title":"Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer\u2019s disease","volume":"5","author":"Chang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109129_bb0485","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.18632\/aging.101944","article-title":"Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients","volume":"11","author":"Tseng","year":"2019","journal-title":"Aging"},{"key":"10.1016\/j.bioorg.2025.109129_bb0490","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.149","article-title":"The impact of acute rosiglitazone on insulin pharmacokinetics at the blood-brain barrier","volume":"3","author":"Galindo","year":"2020","journal-title":"Endocrino Diabet & Metabol"},{"key":"10.1016\/j.bioorg.2025.109129_bb0495","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12987-023-00431-6","article-title":"Central nervous system insulin signaling can influence the rate of insulin influx into brain","volume":"20","author":"Nguyen","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.bioorg.2025.109129_bb0500","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2147\/DMSO.S375559","article-title":"The relationship between the blood-brain-barrier and the central effects of glucagon-like Peptide-1 receptor agonists and sodium-glucose Cotransporter-2 inhibitors","volume":"15","author":"Dong","year":"2022","journal-title":"DMSO"},{"key":"10.1016\/j.bioorg.2025.109129_bb0505","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0510","article-title":"Vesicles of yeast cell wall-sitagliptin to alleviate neuroinflammation in Alzheimer\u2019s disease, nanomedicine: nanotechnology","volume":"44","author":"Mozafari","year":"2022","journal-title":"Biol. Med."},{"key":"10.1016\/j.bioorg.2025.109129_bb0515","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12028-025-02217-0","article-title":"The dipeptidyl Peptidase-4 inhibitor Saxagliptin as a candidate treatment for disorders of consciousness: A deep learning and retrospective clinical analysis","volume":"43","author":"Toker","year":"2025","journal-title":"Neurocrit. Care."},{"key":"10.1016\/j.bioorg.2025.109129_bb0520","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2147\/JIR.S411017","article-title":"Omarigliptin protects the integrity of the blood\u2013brain barrier after intracerebral hemorrhage in mice","volume":"16","author":"Zhang","year":"2023","journal-title":"JIR"},{"key":"10.1016\/j.bioorg.2025.109129_bb0525","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.brainresbull.2022.01.017","article-title":"Dapagliflozin diminishes memory and cognition impairment in Streptozotocin induced diabetes through its effect on Wnt\/\u03b2-catenin and CREB pathway","volume":"181","author":"El-Safty","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bioorg.2025.109129_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123341","article-title":"Insights into the lipophilicity of four commonly prescribed antidiabetic drugs and their simultaneous analysis using a simple TLC-spectrodensitometric method: application to fixed-dose combination tablets and human plasma","volume":"1206","author":"Hosny","year":"2022","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.bioorg.2025.109129_bb0535","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3390\/cells14070511","article-title":"Oxidative stress and redox imbalance: common mechanisms in Cancer stem cells and neurodegenerative diseases","volume":"14","author":"Selvaraj","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109129_bb0540","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3390\/cells12162041","article-title":"The role of c-Abl tyrosine kinase in brain and its pathologies","volume":"12","author":"Motaln","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109129_bb0545","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mds.28858","article-title":"Parkinson\u2019s disease modification through Abl kinase inhibition: an opportunity","volume":"37","author":"Werner","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bioorg.2025.109129_bb0550","doi-asserted-by":"crossref","first-page":"29","DOI":"10.51847\/TWysUbD6PP","article-title":"Modern pharmacological treatment of Parkinson\u2019s disease\u00a0: reviving known drugs and new perspectives","volume":"13","author":"Lastovetskyi","year":"2024","journal-title":"Int J Pharm Res Allied Sci"},{"key":"10.1016\/j.bioorg.2025.109129_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108025","article-title":"Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson\u2019s disease models","volume":"99","author":"Wu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0560","doi-asserted-by":"crossref","unstructured":"Fernando.L. Pagan, M.L. Hebron, B. Wilmarth, Y. Torres-Yaghi, A. Lawler, E.E. Mundel, N. Yusuf, N.J. Starr, M. Anjum, J. Arellano, H.H. Howard, W. Shi, S. Mulki, T. Kurd-Misto, S. Matar, X. Liu, J. Ahn, C. Moussa, Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: A phase 2 randomized clinical trial, JAMA Neurol. 77 (2020) 309. Doi: https:\/\/doi.org\/10.1001\/jamaneurol.2019.4200.","DOI":"10.1001\/jamaneurol.2019.4200"},{"key":"10.1016\/j.bioorg.2025.109129_bb0565","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/ph18060829","article-title":"Synergistic autophagy-related mechanisms of protection against brain aging and AD: cellular pathways and therapeutic strategies","volume":"18","author":"Cordos","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2025.109129_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2025.173966","article-title":"Combination treatment with rapamycin and glucocorticoid protects the death of mesostriatal dopaminergic neurons in animal model of Parkinson\u2019s disease","volume":"248","author":"Lee","year":"2025","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bioorg.2025.109129_bb0575","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jpp\/rgac103","article-title":"Research progress on pharmacological effects of isoalantolactone","volume":"75","author":"Xu","year":"2023","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0580","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3390\/cells11182927","article-title":"Isoalantolactone (IAL) regulates neuro-inflammation and neuronal apoptosis to curb pathology of Parkinson\u2019s disease","volume":"11","author":"He","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109129_bb0585","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1593\/tlo.09280","article-title":"Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with Imatinib","volume":"3","author":"Kast","year":"2010","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.470","article-title":"Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson\u2019s disease","volume":"7","author":"Pagan","year":"2019","journal-title":"Pharmacology Res & Perspec"},{"key":"10.1016\/j.bioorg.2025.109129_bb0595","doi-asserted-by":"crossref","DOI":"10.1002\/trc2.12296","article-title":"Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies","volume":"8","author":"Pagan","year":"2022","journal-title":"A&D Transl. Res. Clin. Interv."},{"key":"10.1016\/j.bioorg.2025.109129_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113605","article-title":"Exosomal delivery of rapamycin modulates blood-brain barrier penetration and VEGF axis in glioblastoma","volume":"381","author":"Song","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioorg.2025.109129_bb0605","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/248532","article-title":"Targeting apoptosis pathways in Cancer with Alantolactone and Isoalantolactone","volume":"2013","author":"Rasul","year":"2013","journal-title":"Sci. World J."},{"key":"10.1016\/j.bioorg.2025.109129_bb0610","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/cam4.2013","article-title":"Isoalantolactone inhibits IKK\u03b2 kinase activity to interrupt the NF-\u03baB\/COX-2-mediated signaling cascade and induces apoptosis regulated by the mitochondrial translocation of cofilin in glioblastoma","volume":"8","author":"Xing","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.bioorg.2025.109129_bb0615","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40035-024-00410-3","article-title":"The role of the brain renin-angiotensin system in Parkinson\u2019s disease","volume":"13","author":"Labandeira-Garcia","year":"2024","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.bioorg.2025.109129_bb0620","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1457459","article-title":"Angiotensin type-1 receptor autoantibodies promote alpha-synuclein aggregation in dopaminergic neurons","volume":"15","author":"Lage","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0625","doi-asserted-by":"crossref","first-page":"29","DOI":"10.31083\/j.jin2302029","article-title":"Telmisartan protects mitochondrial function, gait, and neuronal apoptosis by activating the Akt\/GSK3\u03b2\/PGC1\u03b1 pathway in an MPTP-induced mouse model of Parkinson\u2019s disease","volume":"23","author":"Ray","year":"2024","journal-title":"J. Integr. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0630","doi-asserted-by":"crossref","first-page":"262","DOI":"10.52586\/4942","article-title":"Effects of Telmisartan, an AT1 receptor antagonist, on mitochondria-specific genes expression in a mouse MPTP model of parkinsonism","volume":"26","author":"Ray","year":"2021","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.bioorg.2025.109129_bb0635","series-title":"Investigating the Neuroprotective Effects of Telmisartan using the Lipopolysaccharide Rat Model of Parkinson\u2019s Disease","author":"Sudqi","year":"2024"},{"key":"10.1016\/j.bioorg.2025.109129_bb0640","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ana.27159","article-title":"Propranolol reduces Parkinson\u2019s tremor and inhibits tremor-related activity in the motor cortex: A placebo-controlled crossover trial","volume":"97","author":"Van Der Heide","year":"2025","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176573","article-title":"Angiotensin-converting enzyme inhibition prevents l-dopa-induced dyskinesia in a 6-ohda-induced mouse model of Parkinson\u2019s disease","volume":"973","author":"Park","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0650","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ana.27159","article-title":"Propranolol reduces Parkinson\u2019s tremor and inhibits tremor-related activity in the motor cortex: A placebo-controlled crossover trial","volume":"97","author":"Van Der Heide","year":"2025","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109909","article-title":"Neuro-modulatory impact of felodipine against experimentally-induced Parkinson\u2019s disease: possible contribution of PINK1-Parkin mitophagy pathway","volume":"250","author":"Abou-Hany","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2025.109129_bb0660","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/pds.5176","article-title":"Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson\u2019s disease","volume":"30","author":"Visanji","year":"2021","journal-title":"Pharmacoepidemiology Drug"},{"key":"10.1016\/j.bioorg.2025.109129_bb0665","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/biomedicines10030653","article-title":"Shared molecular targets in Parkinson\u2019s disease and arterial hypertension: A systematic review","volume":"10","author":"Tulb\u0103","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2025.109129_bb0670","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.sjbs.2021.04.013","article-title":"Dexmedetomidine protects against degeneration of dopaminergic neurons and improves motor activity in Parkinson\u2019s disease mice model","volume":"28","author":"Zhang","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175204","article-title":"Neuroprotective repositioning and anti-tau effect of carvedilol on rotenone induced neurotoxicity in rats: insights from an insilico& in vivo anti-Parkinson\u2019s disease study","volume":"932","author":"Kamal","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0680","first-page":"175","article-title":"Anti-inflammatory action of statins in cardiovascular disease: the role of Inflammasome and toll-like receptor pathways, clinic rev","volume":"60","author":"Koushki","year":"2021","journal-title":"Allerg. Immunol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0685","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2022.3718","article-title":"Evaluation of simvastatin as a disease-modifying treatment for patients with parkinson disease: a randomized clinical trial","volume":"79","author":"Stevens","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.bioorg.2025.109129_bb0690","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1523\/JNEUROSCI.3018-19.2021","article-title":"Gemfibrozil protects dopaminergic neurons in a mouse model of Parkinson\u2019s disease via PPAR\u03b1-dependent astrocytic GDNF pathway","volume":"41","author":"Gottschalk","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0695","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1161\/HYPERTENSIONAHA.121.17595","article-title":"Blood-brain barrier crossing renin-angiotensin system drugs: considerations for dementia and cognitive decline","volume":"78","author":"Glodzik","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.bioorg.2025.109129_bb0700","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.nucmedbio.2012.06.012","article-title":"Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques","volume":"39","author":"Noda","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0705","first-page":"43","article-title":"The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer\u2019s disease: the importance of blood-brain barrier penetration and APOE \u03b54 carrier status, Alz res","volume":"13","author":"Ouk","year":"2021","journal-title":"Therapy"},{"key":"10.1016\/j.bioorg.2025.109129_bb0710","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/1389557516666161025094539","article-title":"Angiotensin mediated oxidative stress and neuroprotective potential of antioxidants and AT1 receptor blockers","volume":"17","author":"Prusty","year":"2017","journal-title":"MRMC"},{"key":"10.1016\/j.bioorg.2025.109129_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e08935","article-title":"Captopril is more effective than perindopril against aluminium chloride induced amyloidogenesis and AD like pathology","volume":"8","author":"Mohapatra","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2025.109129_bb0720","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fnins.2019.00033","article-title":"Central effects of Beta-blockers may be due to nitric oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier","volume":"13","author":"Laurens","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0725","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1038\/s41380-022-01615-6","article-title":"Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders","volume":"27","author":"Colbourne","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bioorg.2025.109129_bb0730","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202401731","article-title":"Blood brain barrier-crossing delivery of Felodipine Nanodrug ameliorates anxiety-like behavior and cognitive impairment in Alzheimer\u2019s disease","volume":"11","author":"He","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0735","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/brainsci11070846","article-title":"The current role of Dexmedetomidine as neuroprotective agent: an updated review","volume":"11","author":"Liaquat","year":"2021","journal-title":"Brain Sci."},{"issue":"2321","key":"10.1016\/j.bioorg.2025.109129_bb0740","first-page":"e1","article-title":"Carvedilol as a potential novel agent for the treatment of Alzheimer\u2019s disease","volume":"32","author":"Wang","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bioorg.2025.109129_bb0745","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/brain\/awac076","article-title":"Blood\u2013brain barrier permeable \u03b2-blockers linked to lower risk of Alzheimer\u2019s disease in hypertension","volume":"146","author":"Beaman","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.bioorg.2025.109129_bb0750","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13041-021-00758-x","article-title":"Simvastatin impairs hippocampal synaptic plasticity and cognitive function in mice","volume":"14","author":"Guo","year":"2021","journal-title":"Mol. Brain"},{"key":"10.1016\/j.bioorg.2025.109129_bb0755","doi-asserted-by":"crossref","first-page":"20560","DOI":"10.1038\/s41598-025-05054-5","article-title":"Repurposing of CNS accumulating drugs gemfibrozil and Doxylamine for enhanced sensitization of glioblastoma cells through modulation of autophagy","volume":"15","author":"Dey","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109129_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110386","article-title":"\u03b2-2 agonist and antagonist adrenoceptors induce neuroprotection in a progressive model of parkinsonism","volume":"271","author":"De Gois","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2025.109129_bb0765","first-page":"282","article-title":"Pharmacological targeting of \u03b22 -adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson\u2019s disease, British","volume":"177","author":"O\u2019Neill","year":"2020","journal-title":"Aust. J. Pharm."},{"key":"10.1016\/j.bioorg.2025.109129_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111207","article-title":"Formoterol attenuated mitochondrial dysfunction in rotenone-induced Parkinson\u2019s disease in a rat model: role of PINK-1\/PARKIN and PI3K\/Akt\/CREB\/BDNF\/TrKB axis","volume":"125","author":"Khidr","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0775","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.apsb.2022.07.021","article-title":"Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson\u2019s disease","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.109129_bb0780","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/pharmaceutics12010035","article-title":"Spatial distribution of (R)-salbutamol in rat brain following nasal and intravenous administration using DESI-MS","volume":"12","author":"Zhang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.109129_bb0785","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fphar.2019.01000","article-title":"Salmeterol, a \u03b22 adrenergic agonist, promotes adult hippocampal neurogenesis in a region-specific manner","volume":"10","author":"Bortolotto","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0790","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3390\/cells10040936","article-title":"The effect of the Clenbuterol\u2014\u03b22-adrenergic receptor agonist on the peripheral blood mononuclear cells proliferation, phenotype, functions, and reactive oxygen species production in race horses in vitro","volume":"10","author":"Witkowska-Pi\u0142aszewicz","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109129_bb0795","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s10194-024-01907-y","article-title":"Formoterol dynamically alters endocannabinoid tone in the periaqueductal gray inducing headache","volume":"25","author":"Peterson","year":"2024","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.bioorg.2025.109129_bb0800","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without Glucocerebrosidase gene mutations: A nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.bioorg.2025.109129_bb0805","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/med.22017","article-title":"Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases","volume":"44","author":"Xiang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2025.109129_bb0810","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11481-025-10176-8","article-title":"Vinpocetine and Lactobacillus attenuated rotenone-induced Parkinson\u2019s disease and restored dopamine synthesis in rats through modulation of oxidative stress, neuroinflammation, and lewy bodies inclusion","volume":"20","author":"Hassan","year":"2025","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0815","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10787-023-01305-x","article-title":"PI3K\/AKT signaling activation by roflumilast ameliorates rotenone-induced Parkinson\u2019s disease in rats","volume":"32","author":"Farid","year":"2024","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.bioorg.2025.109129_bb0820","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12610-024-00245-y","article-title":"Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status","volume":"35","author":"Sansone","year":"2025","journal-title":"Basic Clin. Androl."},{"key":"10.1016\/j.bioorg.2025.109129_bb0825","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.3390\/molecules29184318","article-title":"The effect of chronic treatment with the inhibitor of phosphodiesterase 5 (PDE5), sildenafil, in combination with L-DOPA on asymmetric behavior and monoamine catabolism in the striatum and substantia Nigra of unilaterally 6-OHDA-lesioned rats","volume":"29","author":"Lorenc-Koci","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109129_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110576","article-title":"Papaverine inhibits \u03b1-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP\/P mouse model of Parkinson\u2019s disease","volume":"130","author":"Leem","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109129_bb0835","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejphar.2017.11.041","article-title":"An update on vinpocetine: new discoveries and clinical implications","volume":"819","author":"Zhang","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117707","article-title":"Roflumilast and cognition enhancement: A translational perspective","volume":"181","author":"Prickaerts","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109129_bb0845","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.879649","article-title":"The role of sildenafil in treating brain injuries in adults and neonates","volume":"16","author":"Xiong","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0850","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1006\/bbrc.2001.6029","article-title":"Quantitative analysis of papaverine-mediated blood\u2013brain barrier disruption in rats","volume":"289","author":"Bhattacharjee","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.109129_bb0855","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/cells14020089","article-title":"Molecular mechanisms of Alzheimer\u2019s disease induced by amyloid-\u03b2 and tau phosphorylation along with RhoA activity: perspective of RhoA\/rho-associated protein kinase inhibitors for neuronal therapy","volume":"14","author":"Ahn","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109129_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113481","article-title":"Role of RhoA\/ROCK signaling in Alzheimer\u2019s disease","volume":"414","author":"Cai","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bioorg.2025.109129_bb0865","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.4103\/1673-5374.361539","article-title":"Regulation of enolase activation to promote neural protection and regeneration in spinal cord injury","volume":"18","author":"McCoy","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.bioorg.2025.109129_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00544","article-title":"Fasudil inhibits \u03b1-synuclein aggregation through ROCK-inhibition-mediated mechanisms","volume":"22","author":"Lage","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bioorg.2025.109129_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105256","article-title":"Doxycycline inhibits \u03b1-synuclein-associated pathologies in vitro and in vivo","volume":"151","author":"Dominguez-Meijide","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioorg.2025.109129_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2022.105229","article-title":"Repositioning doxycycline for treating synucleinopathies: evidence from a pre-clinical mouse model","volume":"106","author":"La Vitola","year":"2023","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bioorg.2025.109129_bb0885","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1080\/00207454.2022.2154670","article-title":"Pharmacological approach using doxycycline and tocopherol in rotenone induced oxidative stress, neuroinflammation and Parkinson\u2019s like symptoms","volume":"134","author":"Singh","year":"2024","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109129_bb0890","series-title":"Minocycline Treatment Affects Astrocyte \u2013 microglia \u2013 neuron Interaction and Functional Compensation of Motor Deficits in Rat Model of Combined Fluorocitrate and 6-OHDA Lesion and Early Parkinson\u2019s Disease","author":"Kuter","year":"2025"},{"key":"10.1016\/j.bioorg.2025.109129_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117928","article-title":"Rifampicin and its neuroprotective properties in humans \u2013 A systematic review","volume":"185","author":"Vaezipour","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109129_bb0900","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1080\/01480545.2020.1846549","article-title":"Rifampicin decreases neuroinflammation to maintain mitochondrial function and calcium homeostasis in rotenone-treated zebrafish","volume":"45","author":"Yurtsever","year":"2022","journal-title":"Drug Chem. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0905","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9424582","article-title":"Neuroprotective effect of ceftriaxone on MPTP-induced Parkinson\u2019s disease mouse model by regulating inflammation and intestinal microbiota","volume":"2021","author":"Zhou","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2025.109129_bb0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102387","article-title":"Antimicrobial drugs for Parkinson\u2019s disease: existing therapeutic strategies and novel drugs exploration","volume":"99","author":"Fu","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bioorg.2025.109129_bb0915","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.3390\/cells11213468","article-title":"Rifaximin modifies gut microbiota and attenuates inflammation in Parkinson\u2019s disease: preclinical and clinical studies","volume":"11","author":"Hong","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109129_bb0920","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s12035-021-02351-8","article-title":"Quinacrine and Niclosamide promote neurite growth in midbrain dopaminergic neurons through the canonical BMP-Smad pathway and protect against neurotoxin and \u03b1-Synuclein-induced neurodegeneration","volume":"58","author":"Goulding","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0925","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3389\/fphar.2019.00738","article-title":"Doxycycline for Alzheimer\u2019s disease: fighting \u03b2-amyloid oligomers and Neuroinflammation","volume":"10","author":"Balducci","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0930","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00418-022-02150-9","article-title":"The protective effect of low-dose minocycline on brain microvascular ultrastructure in a rodent model of subarachnoid hemorrhage","volume":"159","author":"Gendosz De Carrillo","year":"2023","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0935","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3390\/pharmaceutics13091479","article-title":"Permeation challenges of drugs for treatment of neurological tuberculosis and HIV and the application of magneto-electric nanoparticle drug delivery systems","volume":"13","author":"Mhambi","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.109129_bb0940","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/antibiotics11121843","article-title":"The blood\u2013brain barrier and pharmacokinetic\/pharmacodynamic optimization of antibiotics for the treatment of central nervous system infections in adults","volume":"11","author":"Haddad","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.bioorg.2025.109129_bb0945","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/HMER.S11988","article-title":"Rifaximin in the treatment of hepatic encephalopathy","author":"Iadevaia","year":"2011","journal-title":"HMER"},{"key":"10.1016\/j.bioorg.2025.109129_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00346","article-title":"Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models","volume":"21","author":"Milani","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bioorg.2025.109129_bb0955","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10787-023-01192-2","article-title":"A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson\u2019s disease: beneficial or detrimental effects","volume":"31","author":"Alrouji","year":"2023","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.bioorg.2025.109129_bb0960","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10787-023-01192-2","article-title":"A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson\u2019s disease: beneficial or detrimental effects","volume":"31","author":"Alrouji","year":"2023","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.bioorg.2025.109129_bb0965","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/pathogens10030268","article-title":"Co-Administration of Gagam-Sipjeondaebo-Tang and Ibuprofen Alleviates the inflammatory response in MPTP-induced Parkinson\u2019s disease mouse model and RAW264.7 macrophages","volume":"10","author":"Won","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.bioorg.2025.109129_bb0970","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1007\/s10787-024-01567-z","article-title":"Repurposing celecoxib as adjuvant therapy in patients with parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study","volume":"32","author":"Khrieba","year":"2024","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.bioorg.2025.109129_bb0975","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114386","article-title":"Genetic evidence of methotrexate\u2019s protective role against Parkinson\u2019s disease: A Mendelian randomization and co-localization study","volume":"152","author":"Zou","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb0985","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41380-024-02618-1","article-title":"Abatacept inhibits Th17 differentiation and mitigates \u03b1-synuclein-induced dopaminergic dysfunction in mice","volume":"30","author":"Clarke","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bioorg.2025.109129_bb0990","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11095-006-9905-5","article-title":"Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, Flurbiprofen, and indomethacin","volume":"23","author":"Parepally","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2025.109129_bb0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2023.102344","article-title":"Celecoxib attenuates neuroinflammation, reactive astrogliosis and promotes neuroprotection in young rats with experimental hydrocephalus","volume":"133","author":"Dutra","year":"2023","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.bioorg.2025.109129_bb1000","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1186\/s12885-019-6228-6","article-title":"Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer","volume":"19","author":"Bazan","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2025.109129_bb1005","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.3390\/ijms21093067","article-title":"Cannabidiol and other non-psychoactive cannabinoids for prevention and treatment of gastrointestinal disorders: useful nutraceuticals?","volume":"21","author":"Mart\u00ednez","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2025.109129_bb1010","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/brainsci11121573","article-title":"The neuroprotective effects of Cannabis-derived Phytocannabinoids and resveratrol in Parkinson\u2019s disease: A systematic literature review of pre-clinical studies","volume":"11","author":"Prakash","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.bioorg.2025.109129_bb1015","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bcpt.13997","article-title":"Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson\u2019s disease and in comorbidity with psychiatric disorders","volume":"134","author":"De F\u00e1tima Dos","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109129_bb1020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/a-1686-9620","article-title":"Opportunities for drug repurposing of serotonin reuptake inhibitors: potential uses in inflammation, infection, Cancer, neuroprotection, and Alzheimer\u2019s disease prevention","volume":"55","author":"Nykamp","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.bioorg.2025.109129_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112715","article-title":"Escitalopram moderately outperforms citalopram towards anti-neuroinflammation and neuroprotection in 6-hydroxydopamine-induced mouse model of Parkinson\u2019s disease","volume":"139","author":"Ovlyakulov","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb1030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21608\/ejchem.2020.47734.2975","article-title":"Modafinil alleviates rotenone-induced neurochemical changes and striatal neurodegeneration via inhibiting oxidative stress and Neuroinflammation","volume":"63","author":"Seadawy","year":"2020","journal-title":"Egypt. J. Chem."},{"key":"10.1016\/j.bioorg.2025.109129_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.109841","article-title":"Modulation of histone deacetylase, the ubiquitin proteasome system, and autophagy underlies the neuroprotective effects of venlafaxine in a rotenone-induced Parkinson\u2019s disease model in rats","volume":"354","author":"El-Saiy","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2025.109129_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2023.102315","article-title":"Caffeine alleviates anxiety-like behavior and brainstem lesions in a rotenone-induced rat model of Parkinson\u2019s disease","volume":"132","author":"Adeyeye","year":"2023","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.bioorg.2025.109129_bb1045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/08919887231154933","article-title":"Comparative efficacy, safety, and acceptability of Pimavanserin and other atypical antipsychotics for Parkinson\u2019s disease psychosis: systematic review and network Meta-analysis","volume":"36","author":"Yunusa","year":"2023","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.bioorg.2025.109129_bb1050","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/brainsci12101286","article-title":"Fornari Caprara, Pimavanserin and Parkinson\u2019s disease psychosis: A","volume":"12","author":"Rissardo","year":"2022","journal-title":"Narrative Review, Brain Sci."},{"key":"10.1016\/j.bioorg.2025.109129_bb1055","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/ijms23031845","article-title":"The anxiolytic drug Buspirone prevents rotenone-induced toxicity in a mouse model of Parkinson\u2019s disease","volume":"23","author":"Thomas Broome","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2025.109129_bb1060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/pharmaceutics12030265","article-title":"Cannabinoids, blood\u2013brain barrier, and brain disposition","volume":"12","author":"Calapai","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.109129_bb1065","first-page":"349","article-title":"Pharmacokinetic modelling of blood\u2013brain barrier transport of escitalopram in rats, Biopharm & Drug","volume":"28","author":"Bundgaard","year":"2007","journal-title":"Disp"},{"key":"10.1016\/j.bioorg.2025.109129_bb1070","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.euroneuro.2010.04.004","article-title":"Blood\u2013brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein","volume":"20","author":"Karlsson","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bioorg.2025.109129_bb1075","article-title":"Pharmacokinetics of novel dopamine transporter inhibitor CE-123 and Modafinil with a focus on central nervous system distribution","volume":"24","author":"Spreitzer","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2025.109129_bb1080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bbr.2016.06.011","article-title":"A novel heterocyclic compound targeting the dopamine transporter improves performance in the radial arm maze and modulates dopamine receptors D1-D3","volume":"312","author":"Saroja","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bioorg.2025.109129_bb1085","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/ijms23031862","article-title":"Central nervous system stimulants limit caffeine transport at the blood\u2013cerebrospinal fluid barrier","volume":"23","author":"Ikeda-Murakami","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2025.109129_bb1090","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","article-title":"On the discovery and development of Pimavanserin: A novel drug candidate for Parkinson\u2019s psychosis","volume":"39","author":"Hacksell","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bioorg.2025.109129_bb1095","article-title":"Development and evaluation of buspirone hydrochloride nanoparticle temperature-sensitive gel for treating generalized anxiety disorder","volume":"114","author":"Tong","year":"2025","journal-title":"J. Drug Del. Sci. Technol."},{"key":"10.1016\/j.bioorg.2025.109129_bb1100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12017-024-08785-2","article-title":"Effect of Clemizole on alpha-Synuclein-preformed fibrils-induced Parkinson\u2019s disease pathology: A pharmacological investigation","volume":"26","author":"Vaidya","year":"2024","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.bioorg.2025.109129_bb1105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuro.2024.11.005","article-title":"Acyclovir provides protection against 6-OHDA-induced neurotoxicity in SH-SY5Y cells through the kynurenine pathway","volume":"106","author":"Sezen","year":"2025","journal-title":"NeuroToxicology"},{"key":"10.1016\/j.bioorg.2025.109129_bb1110","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s10787-022-01011-0","article-title":"Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action","volume":"30","author":"Mu\u00f1oz-Jurado","year":"2022","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.bioorg.2025.109129_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2025.115600","article-title":"Melatonin protects dopaminergic neurons in paraquat-induced Parkinson in rats through PI3K\/AKT\/Nrf2 pathway","volume":"203","author":"Wang","year":"2025","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109129_bb1120","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5577541","article-title":"Effect of melatonin administration on mitochondrial activity and oxidative stress markers in patients with Parkinson\u2019s disease","volume":"2021","author":"Jim\u00e9nez-Delgado","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2025.109129_bb1125","first-page":"89","article-title":"Effects of tropicamide on catalepsy and motor function in a mouse model of Parkinson\u2019s disease, aging","volume":"2","author":"Corr\u00eaa","year":"2025","journal-title":"Advances"},{"key":"10.1016\/j.bioorg.2025.109129_bb1130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.brainresbull.2020.12.011","article-title":"Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson\u2019s disease","volume":"168","author":"Vecchia","year":"2021","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bioorg.2025.109129_bb1135","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113810","article-title":"Memantine exerts neuroprotective effects by modulating \u03b1-synuclein transmission in a parkinsonian model","volume":"344","author":"Lee","year":"2021","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bioorg.2025.109129_bb1140","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/pds.5015","article-title":"Identifying drugs with disease-modifying potential in Parkinson\u2019s disease using artificial intelligence and pharmacoepidemiology","volume":"29","author":"Maclagan","year":"2020","journal-title":"Pharmacoepidemiology Drug"},{"key":"10.1016\/j.bioorg.2025.109129_bb1145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s44163-025-00241-9","article-title":"A review of machine learning and deep learning for Parkinson\u2019s disease detection","volume":"5","author":"Rabie","year":"2025","journal-title":"Discov. Artif. Intell."},{"key":"10.1016\/j.bioorg.2025.109129_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117862","article-title":"An update on drug repurposing in Parkinson\u2019s disease: preclinical and clinical considerations","volume":"183","author":"Salvad\u00e8","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109129_bb1155","doi-asserted-by":"crossref","DOI":"10.1007\/s11030-024-11090-6","article-title":"Integrating network pharmacology with molecular docking and dynamics to uncover therapeutic targets and signaling mechanisms of vitamin D3 in Parkinson\u2019s disease","author":"Wang","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2025.109129_bb1160","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3390\/ph18060788","article-title":"The potential of artificial intelligence in pharmaceutical innovation: from drug discovery to clinical trials","volume":"18","author":"Malheiro","year":"2025","journal-title":"Pharmaceuticals"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T19:05:49Z","timestamp":1763665549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825010090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":232,"alternative-id":["S0045206825010090"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109129","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic innovation through drug repurposing: A multidimensional approach toward treating Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109129"}}